FeelGood GLP-1 Review 2026: $149/Month Compounded Program, What FDA's June 2026 503B Proposal Changes for Buyers, and a 20-Question Enrollment Checklist

DES MOINES, Iowa, June 9, 2026 (Newswire.com) - Title Reference Notice: "FeelGood GLP-1" is the consumer-facing product identifier published by FeelGood Health at feelgoodmeds.com. "Advertorial Review 2026" identifies this as a sponsored advertorial. "$149/Month Brand-Stated Starting Price" reflects FeelGood's published starting price for compounded injections - actual cost may vary by dosage and program tier; verify at checkout. "20 Buyer Verification Questions" refers to the buyer checklist in this article. "FDA's June 2026 Compounding Proposal" refers to the FDA's publicly announced proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list, with a public comment period open through June 2026 - this is a factual regulatory event documented in the Federal Register and at FDA.gov, not a determination specific to FeelGood. "Before You Enroll" refers to the buyer due-diligence framework in this article. This publication does not independently substantiate FeelGood's performance claims.

Advertorial Disclosure: This article is promotional in nature and is intended for consumer education regarding a commercially available telehealth service. This article contains affiliate links. A commission may be earned on qualifying purchases or enrollments made through links in this content, at no additional cost to the reader. FeelGood GLP-1 programs involve prescription medications. Prescription medication is available only after consultation and approval by a licensed healthcare provider, if clinically appropriate. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Individual results vary. This content is not medical advice. Disclosure provided in accordance with FTC 16 CFR Part 255.

FeelGood GLP-1 2026 Research Explores Brand-Stated $149/Month Telehealth Access, Compounded Medication Disclosures, and Buyer Questions

Why This Review Exists Right Now - and Why Timing Matters for GLP-1 Buyers in 2026

FDA has publicly identified concerns involving unapproved and compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent compounded products, adverse-event reports, semaglutide salt forms, and illegal online sales. As of April 2026, FDA formally proposed - in a Federal Register notice (91 Fed. Reg. 23431, docket 2026-08552, published May 1, 2026) - removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list, with a public comment period through June 2026. If that proposal is finalized, large-scale compounded GLP-1 availability through 503B outsourcing facilities changes significantly. That's the regulatory environment every compounded GLP-1 telehealth platform operates in right now - including the one you're researching - and it's why the timing of your enrollment decision matters in a way it didn't a year ago.

This article does not state that FeelGood has or has not received any specific FDA communication. Consumers should rely on FDA.gov, FeelGood support, and their licensed provider for current regulatory information. FeelGood's site displays a LegitScript verification reference (verifiable at legitscript.com), a transparent three-entity structure, and a publicly documented medical group (OpenLoop Healthcare Partners, PC) - all of which are public signals consumers can independently review. But the regulatory pressure doesn't stop at the named companies - it's reshaping what buyers need to verify before enrolling anywhere, and it's accelerating the timeline for doing that due diligence.

That's what makes this article different from the ones written before this environment existed. If you're comparing compounded GLP-1 programs in mid-2026, the useful question isn't just "does this platform seem legit?" It's "what has this platform publicly disclosed, and does that match what FDA says buyers should verify?" That's the framework this review gives you - for FeelGood specifically, and for any platform you're comparing it against.

Buyer Takeaway: The compounded GLP-1 telehealth space contracted materially between 2025 and mid-2026. FDA's April 2026 proposal to remove semaglutide and tirzepatide from the 503B bulks list - with a public comment period through June 2026 - creates a genuine decision window: buyers who enroll now are committing to a subscription before the outcome of that proposal is known. That's not manufactured urgency. That's the current regulatory calendar. Knowing what to verify before you enroll is the difference between a well-informed subscription decision and one made without the relevant context.

TL;DR - What You Need to Know About FeelGood GLP-1 in 60 Seconds

FeelGood GLP-1 is a telehealth platform connecting patients with licensed medical providers for evaluation and, when clinically appropriate, access to compounded GLP-1 injections starting at $149 per month - in a category where FDA formally proposed in April 2026 removing semaglutide and tirzepatide from the 503B outsourcing bulks list - with a public comment period open through June 2026. If finalized, large-scale compounded GLP-1 availability through 503B facilities changes significantly. This article does not state whether FeelGood has or has not received any specific FDA communication. Compounded GLP-1 medications are not FDA-approved. The brand reports 15-20% average body weight loss - brand-stated, not independently verified. You can cancel any time with 72-hour notice. Free shipping and HSA/FSA eligibility are brand-stated. The official lander references a "Weight Loss Money Back Guarantee," while the published refund policy limits refunds once medication has been ordered. Buyers should confirm guarantee terms directly with FeelGood before enrollment.

View the current FeelGood GLP-1 offer (official FeelGood page)

FeelGood GLP-1 2026 Fast Facts: What Every Buyer Should Know in 30 Seconds

• Platform name: FeelGood (operated by FeelGood Health)

• Program type: Telehealth subscription - prescription GLP-1 weight loss program

• Medical group: OpenLoop Healthcare Partners, PC (Des Moines, Iowa)

• Pricing - Compounded Injections: Starting at $149/month (brand-stated)

• Pricing - Compounded Tablets: Starting at $249/month (brand-stated)

• Pricing - Original Injections: Starting at $1,999/month (brand-stated; limited availability)

• Compounded medication status: NOT FDA-approved - compounded medications are prepared by third-party licensed pharmacies and are not subject to FDA approval or review for safety, effectiveness, or quality

• First step: Online intake evaluation; clinician review; prescription issued if clinically appropriate

• Consultation requirement: Virtual consultation with a licensed healthcare provider required before any prescription

• Shipping: Free shipping (brand-stated)

• Insurance required: No - brand states no insurance required

• HSA/FSA eligible: Yes (brand-stated)

• Average weight loss (brand-reported): 15-20% of body weight - brand-stated, not independently verified

• Patient base (brand-reported): 100,000+ patients - brand-stated

• Rating (brand-reported): 4.8/5 Excellent - brand-stated

• Cancellation: Any time; email support@feelgoodmeds.com; 72-hour notice required before billing date

• LegitScript reference: FeelGood's official site displays a LegitScript verification reference; consumers should verify current status directly through LegitScript before enrollment

• App available: Yes - iOS App Store and Google Play

• Support: 24/7 access to support team (brand-stated)

• Contact: support@feelgoodmeds.com

• Governing law: State of Iowa (per Terms of Use)

• "USA Made" claim: Appears on official lander; specific manufacturing origin of compounded medications not confirmed in publicly available documentation - buyers should verify directly

• FDA compounding regulatory status (June 2026): Semaglutide and tirzepatide shortage determinations resolved in 2025; neither drug on current FDA shortage or 503B bulks list; FDA formally proposed on April 30, 2026 removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list (Federal Register notice published May 1, 2026: 91 Fed. Reg. 23431, docket 2026-08552; public comment period through June 2026); if finalized, large-scale 503B compounding of these drugs changes significantly - verify current status at FDA.gov before enrolling; LegitScript-verified

• Data privacy - OpenLoop Healthcare Partners (January 2026): FeelGood's telehealth services involve OpenLoop Healthcare Partners, PC as the medical group; consumers should review OpenLoop's telehealth consent at openloophealth.com/telehealth-consent and ask FeelGood support specific data privacy questions before enrollment

• FDA compounded GLP-1 adverse events: The FDA received 1,150+ adverse event reports related to compounded semaglutide/tirzepatide as of July 2025, including dosing errors with vial-based injectables; confirm dosing and measurement instructions with provider before first injection

• Product quality/impurity risk: Litigation filed in early 2026 alleges compounded injectable semaglutide tested at impurity levels as high as 86% - allegations in pending litigation, not FDA findings about FeelGood's specific pharmacy; ask for a Certificate of Analysis (CoA) before your first dose

• Semaglutide API form to verify: Ask your provider whether the compounded product uses base-form semaglutide, not unapproved salt forms (semaglutide sodium/acetate), which the FDA states have no known lawful basis for use in compounding

• FTC GLP-1 telehealth enforcement: The FTC finalized a December 2025 enforcement action against telehealth platform NextMed for undisclosed subscription costs and unsubstantiated GLP-1 weight loss claims; confirm all-in pricing includes medication before first charge

View the current FeelGood GLP-1 offer (official FeelGood page)

About the Promotional Language on FeelGood's Website

If you arrived at this article from a FeelGood ad, a social campaign, or a paid search result, you likely saw some bold marketing language on the way here. Words like "Fat loss made easy," "Clinician Prescribed," "Weight Loss Money Back Guarantee," "No membership or hidden fees," and "15-20% average weight loss" are displayed prominently on the brand's official website at feelgoodmeds.com.

This article uses FeelGood's own product name and category positioning to identify the program you're researching. Here's what each of those phrases actually means - and what it doesn't mean - before you make any decision:

• "Fat loss made easy" - Brand positioning language describing the program's enrollment process (online intake, no office visit required, home delivery). It does not mean weight loss occurs without effort or that results are guaranteed. Per the brand's own site: "Prescription medications require a virtual consultation and approval by a licensed healthcare provider. Results may vary."

• "Clinician Prescribed" - Accurate description of the process: a licensed healthcare provider evaluates your intake and issues a prescription if clinically appropriate. Prescription is not guaranteed. FeelGood does not prescribe - OpenLoop Healthcare Partners, PC and its affiliated providers do.

• "Weight Loss Money Back Guarantee" - This phrase appears on the lander. The published refund policy states that fees are generally non-refundable once medication has been ordered. Buyers should contact support@feelgoodmeds.com before enrolling to confirm the specific terms of any guarantee that may apply to their program tier.

• "15-20% average weight loss" - Brand-reported figure. This is not an independently verified or audited statistic. Individual results vary. GLP-1 medications have been studied in clinical trials, but this specific platform's outcomes figure has not been independently confirmed by this publication.

• "No membership or hidden fees" - Brand-stated. Buyers should confirm whether evaluation fees, consultation fees, or pharmacy fees are bundled into the subscription price or billed separately. The refund policy confirms "all-in" subscription pricing in its FAQ but buyers should verify at checkout.

• "USA Made" - Appears on the lander. FeelGood Health is a US-based platform. OpenLoop Healthcare Partners, PC is headquartered in Des Moines, Iowa. The specific compounding pharmacy fulfilling prescriptions is a third-party entity whose location has not been confirmed in publicly available FeelGood documentation. Buyers seeking to confirm manufacturing origin should contact support@feelgoodmeds.com directly.

Buyer Takeaway: The promotional language on FeelGood's website describes the brand's market positioning and the general patient experience the platform is designed to deliver. It does not guarantee individual outcomes, clinician approval, or specific results. This article distinguishes between what the brand states, what is verifiable through public documentation, and what requires direct buyer confirmation before enrolling.

Quick Verification Snapshot - FeelGood GLP-1 (As of June 2026)

• Official website: feelgoodmeds.com (publicly accessible)

• Affiliate link verified: https://newsdirectonline.com/feelgood-glp-1

• LegitScript seal: Present and displayed on official site - verifiable at legitscript.com

• Medical group on record: OpenLoop Healthcare Partners, PC - Des Moines, Iowa; telehealth consent publicly posted at openloophealth.com/telehealth-consent

• Refund policy: Publicly posted at feelgoodmeds.com/refund-policy

• Terms of Use: Publicly posted at feelgoodmeds.com/terms-of-use; last updated July 2025; governing law Iowa

• Compounded medication disclosure: Per OpenLoop telehealth consent: "The FDA does not approve nor review compounded products for safety, effectiveness, or quality"

• Cancellation method: Email support@feelgoodmeds.com; 72-hour notice before billing date required

• App download: Available on iOS App Store and Google Play

• Prior Accesswire/Newswire coverage: None detected - first release

• Conflict flag: "Weight Loss Money Back Guarantee" on lander vs. refund policy language limiting refunds once medication ordered - buyers should confirm guarantee terms directly before enrolling

• Data privacy flag: Medical group infrastructure partner FeelGood's telehealth services process health data through OpenLoop Healthcare Partners, PC - consumers should ask data privacy questions at support@feelgoodmeds.com before enrollment

• FDA dosing error advisory: Compounded injectable GLP-1s require patient self-measurement from vials; FDA has documented adverse events including overdoses from dosing errors - get explicit measurement guidance from provider before first injection

• FTC precedent: FTC December 2025 NextMed enforcement action involved undisclosed GLP-1 subscription costs; confirm all-in $149 price includes medication before first charge

• FDA regulatory status (as of June 2026): FDA formally proposed on April 30, 2026 removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list (Federal Register notice published May 1, 2026: 91 Fed. Reg. 23431, docket 2026-08552; public comment period through June 2026); if finalized, 503B compounding of these drugs changes significantly; 503A pathway requires prescriber documentation of "significant difference" from commercially available product - verify current proposal status at FDA.gov before enrolling

What Is FeelGood GLP-1 and Who Is Behind It?

FeelGood is a telehealth platform built around one core appeal: clinician-supervised GLP-1 treatment you can access from your phone without insurance, without a doctor's office, and without the $900-plus monthly price tag most people associate with these medications. The $149/month starting price for compounded injections is the number that gets attention - and it's real, according to the brand's published pricing. But getting to that price and staying there involves understanding what you're actually enrolling in.

One thing to be clear on before anything else: FeelGood operates the platform. OpenLoop Healthcare Partners, PC and affiliated licensed providers make all clinical decisions. FeelGood does not prescribe medication. That distinction matters for every question you'll have during your experience on the platform - who to call about a side effect, who issued your prescription, and who bears clinical responsibility for your treatment.

Understanding the three-entity structure that makes a program like FeelGood work, because knowing who does what matters when you're evaluating a telehealth weight loss service - particularly when something goes wrong or you have a clinical question that requires a faster answer than a general support queue can provide. FeelGood Health operates the technology platform - the website, the patient portal, the app, and the support infrastructure that routes your questions and coordinates your care. OpenLoop Healthcare Partners, PC is the licensed medical group that employs or contracts the licensed providers who evaluate your intake form and, when appropriate in their independent clinical judgment, issue prescriptions for GLP-1 medication. A third-party compounding pharmacy then prepares and ships your specific medication according to the prescription issued by your provider.

According to FeelGood's published Terms of Use, "FeelGood does not provide any medical services... All Providers who deliver Healthcare Services through the Site are (1) independent practitioners contracted or employed with affiliated Medical Groups that coordinate with FeelGood, and (2) solely responsible for the Healthcare Services you receive." That's standard legal architecture for telehealth platforms and it matters to understand: the evaluation, the prescription decision, and the clinical responsibility rest with the licensed providers, not with FeelGood's business entity.

FeelGood's official site displays a LegitScript verification reference. Consumers should verify current status directly at legitscript.com before enrollment - certification status can change over time.

Buyer Takeaway: FeelGood is a platform connecting you to licensed providers and a compounding pharmacy - not a direct medical provider. Understanding the three-entity structure helps you know who to contact with clinical questions (your provider, via the platform), billing questions (FeelGood support), and medication concerns (FeelGood support, who coordinates with the pharmacy).

Telehealth Data Privacy and Security: Questions FeelGood Consumers Should Ask Before Enrollment

Because GLP-1 telehealth programs involve sensitive health information shared with a platform, a medical group, and a compounding pharmacy, data privacy and security are legitimate buyer due-diligence topics. Before enrolling in any telehealth GLP-1 program, consumers should review the platform's privacy policy, telehealth consent materials, and any medical group or technology partner disclosures.

Useful questions to ask FeelGood before enrollment include: Who stores patient intake and health information? Which medical group reviews that information, and what are their data-security practices? Which pharmacy receives prescription details? How are provider and support messages handled and stored? What notice would patients receive if data practices materially change?

FeelGood's telehealth services are provided through OpenLoop Healthcare Partners, PC. Consumers who want to understand OpenLoop's data practices can review the telehealth consent form published at openloophealth.com/telehealth-consent. Consumers may also contact FeelGood support at support@feelgoodmeds.com with specific data privacy questions before sharing health information.

This article recommends that any consumer who has questions about how their health information is handled by FeelGood, OpenLoop Healthcare Partners, or any associated pharmacy contact support@feelgoodmeds.com in writing before enrolling, and retain those written responses for their records.

Buyer Takeaway: Telehealth GLP-1 programs require sharing sensitive health information with a platform, a licensed medical group, and a compounding pharmacy. Before enrolling in FeelGood, ask in writing how your data is stored, who has access, and what notification you would receive if data practices change. Contact support@feelgoodmeds.com with specific data privacy questions and retain written responses.

How FeelGood's GLP-1 Program Works: The Enrollment Process

The brand describes a three-step process on its official website: get approved, get prescribed, receive your medication. Here's what each step actually means, based on publicly available documentation.

You start with an online intake evaluation - a questionnaire that collects your health history, current medications, and weight loss goals. A licensed provider from OpenLoop Healthcare Partners, PC reviews your submission. If you require a live video visit, that's scheduled; some evaluations are handled asynchronously through form review. The provider makes an independent clinical judgment about whether GLP-1 medication is appropriate for you. Per the brand's Terms: "After reviewing your information, the Provider in their independent professional judgment, will determine whether to prescribe medication, other treatments, or, alternatively, recommend that you consult with alternative clinical resources." Prescription is not guaranteed.

If you're approved and a prescription is issued, your medication is shipped from a licensed compounding pharmacy directly to your door. FeelGood states free shipping is included. Delivery timeline isn't specified in publicly available documentation - buyers should confirm with support before enrolling if timing is a factor.

The platform also offers a mobile app on iOS and Google Play for managing your care, communicating with support, and tracking your progress. Brand-stated 24/7 support access is included in the subscription.

Quick Answer: How does FeelGood's enrollment process work?

FeelGood's enrollment involves completing an online health evaluation, which a licensed provider from OpenLoop Healthcare Partners, PC reviews to determine clinical eligibility. If a GLP-1 prescription is deemed appropriate, medication is shipped from a licensed compounding pharmacy. The process doesn't require an in-person office visit or health insurance, and compounded injections start at $149 per month according to the brand's published pricing.

Buyer Takeaway: You won't know if you're approved until a licensed provider reviews your intake. FeelGood's published Terms explicitly state that approval is not guaranteed. Budget for the consultation and first month, and be aware that if you're disqualified for medical reasons before medication is ordered, the brand states a full refund is available.

What Kind of Medication Does FeelGood Offer?

FeelGood offers three program tiers based on the type of GLP-1 medication: Compounded Injections at $149/month, Compounded Tablets at $249/month, and Original Injections at $1,999/month (listed with limited and variable availability). The first two tiers are compounded formulations. The third is brand-name. That distinction is the most important sentence in this section.

The distinction between "compounded" and "original" is important for buyers to understand - and it's a distinction the telehealth GLP-1 market doesn't always explain clearly enough. Compounded medications are custom-prepared by a licensed compounding pharmacy using active pharmaceutical ingredients sourced from FDA-registered facilities, but the finished compounded product itself doesn't go through the FDA's new drug approval process for safety, effectiveness, and manufacturing quality the way brand-name medications like Ozempic or Wegovy do. Per the telehealth consent published by OpenLoop Healthcare Partners, PC: "The FDA does not approve nor review compounded products for safety, effectiveness, or quality." Compounding pharmacies are licensed and subject to state pharmacy board regulations and federal law under the Drug Quality and Security Act, but the oversight framework is meaningfully different from the pre-market approval process that governs brand-name drugs - and buyers who understand that distinction can ask better questions before their first shipment arrives.

The brand's lander references "Semaglutide+" as a program name, but specific drug names and dosages aren't confirmed in publicly accessible FeelGood documentation reviewed for this article. Buyers should ask their assigned provider directly about the specific medication, dosage protocol, and titration schedule before starting - because the titration timeline (how quickly your dose increases toward a therapeutic target) affects both tolerability and expected timeline to meaningful weight change.

Buyers considering the Compounded Tablets tier at $249/month should be aware of a specific pending litigation development. A class-action complaint filed in November 2025 against OpenLoop Health and Triad Rx - the medical group infrastructure and pharmacy involved in a separate telehealth platform - alleges that compounded oral tirzepatide tablets have no viable absorption pathway and therefore cannot produce a therapeutic effect. These are allegations in pending litigation, not proven findings, and they involve a different platform's specific formulation. The underlying scientific question - whether oral compounded peptide medications have sufficient bioavailability to produce clinically meaningful GLP-1 effects - is an appropriate question to ask your assigned provider directly before starting any compounded oral GLP-1 program, including FeelGood's Compounded Tablets tier.

Quick Answer: Are FeelGood's GLP-1 medications FDA-approved?

FeelGood's compounded GLP-1 injections and tablets are not FDA-approved. According to the telehealth consent published by OpenLoop Healthcare Partners, PC, the licensed medical group partnering with FeelGood, the FDA does not approve, review, or evaluate compounded medications for safety, effectiveness, or quality. Compounding pharmacies are licensed under state and federal regulations, but compounded products occupy a distinct regulatory category from brand-name FDA-approved drugs. Buyers should factor this distinction into their decision and discuss it with their assigned provider.

Buyer Takeaway: Compounded GLP-1 medications are a legal, widely used route for patients who can't access or afford brand-name FDA-approved GLP-1 drugs. But the regulatory difference is real and should be part of your informed consent conversation with your provider - not something you discover after your first shipment arrives.

FeelGood GLP-1 Pricing: What Does It Actually Cost?

The three pricing tiers published on FeelGood's official website as of June 2026 are:

• Compounded Injections: Starting at $149/month

• Compounded Tablets: Starting at $249/month

• Original Injections: Starting at $1,999/month (noted as limited availability; "availability is subject to change")

These are brand-stated "starting at" prices - the actual cost may vary based on dosage, titration level, and program tier. Buyers should verify the specific price at checkout before completing enrollment. Shipping is described as free by the brand. The brand also states HSA/FSA eligibility. Tax is calculated separately at checkout in applicable jurisdictions. Comparison prices to brand-name GLP-1 medications (which can run $900-$1,300+ per month without insurance) are the brand's own reference points and may not reflect prevailing market prices in all circumstances.

The subscription model means you're billed on a recurring cycle. The brand's Terms of Use confirm this is a subscription with monthly charges beginning when you complete the intake form. The brand states there are "no membership or hidden fees" and that "everything you need is included" - buyers should confirm exactly what's bundled at their specific tier (consultation, medication, shipping, support) versus billed separately.

Critical pricing verification - the NextMed precedent: In December 2025, the FTC finalized an enforcement action against a GLP-1 telehealth company (NextMed) partly because it advertised a monthly membership price that did not include the actual cost of the GLP-1 drug, lab work, or provider consultation fees. Those costs were separate and weren't adequately disclosed upfront. Before you enroll in FeelGood, confirm specifically and in writing: does the $149/month price include the compounded medication itself? Does it include provider consultation fees? Are there any lab work costs billed separately? FeelGood's published Refund Policy FAQ states that the Subscription Service price may include "provider evaluation and prescribing," "medication fulfillment," and "care coordination" - which suggests bundled pricing. But "may include" and "starting at" together mean you should confirm the all-in cost for your specific tier at checkout and get confirmation in writing before recurring billing begins.

Buyer Takeaway: FeelGood advertises $149/month as its starting price for compounded injections. Confirm that this price includes the compounded medication itself - not just the consultation - before your first charge. The FTC's December 2025 enforcement action against NextMed was specifically about failure to disclose that an advertised telehealth price didn't include medication costs. Don't assume; verify.

View the current FeelGood GLP-1 offer (official FeelGood page)

The Money Back Guarantee: What Buyers Need to Verify

The "Weight Loss Money Back Guarantee" is front-and-center on FeelGood's homepage. If you came here from an ad, you probably saw it. And it sounds like exactly the kind of safety net that makes enrolling in a subscription medication program feel lower-risk.

Here's the conflict that buyers should know about before enrolling. The brand's published Cancellation and Refund Policy, accessible at feelgoodmeds.com/refund-policy, states the following: "EXCEPT AS OTHERWISE SET FORTH IN ANY RETURN OR REFUND POLICY PROVIDED TO YOU ON THE SERVICES, YOU ACKNOWLEDGE AND AGREE THAT DUE TO THE NATURE OF THE PRODUCTS AND SERVICES PURCHASABLE THROUGH THE SERVICES ANY APPLICABLE FEES AND OTHER CHARGES ARE NOT REFUNDABLE." Refunds are specifically available when: medication has not yet been ordered, or a licensed provider disqualifies you for medical reasons before medication is ordered.

Once your medication has been ordered, no refund is available. Federal pharmaceutical regulations prohibit the return of prescription medications to pharmacies - and FeelGood's policy correctly reflects that regulatory reality. The policy also specifies that if you don't provide 72-hour advance notice before your billing date, you'll be charged for the next cycle even if you've cancelled, with the cancellation taking effect on the next billing cycle after that.

The gap between the "Weight Loss Money Back Guarantee" marketing language and the published refund policy terms is something this publication can't resolve - it requires a direct conversation with FeelGood's support team before you enroll. Ask specifically: what are the terms of the weight loss money back guarantee, how do you claim it, and what conditions apply?

Quick Answer: Does FeelGood offer a money-back guarantee?

FeelGood's lander prominently features a "Weight Loss Money Back Guarantee," but the published Cancellation and Refund Policy at feelgoodmeds.com/refund-policy states that fees are generally non-refundable once medication has been ordered. Refunds are available if a provider disqualifies you for medical reasons before medication is ordered, or if you cancel before medication is ordered. Buyers should contact support@feelgoodmeds.com before enrolling to confirm the specific terms and eligibility requirements of any weight loss money-back guarantee that may apply to their chosen program tier.

Buyer Takeaway: Don't assume the "Money Back Guarantee" language on the homepage reflects unconditional refund rights. Get the specific terms in writing from FeelGood support before your first billing cycle. The published refund policy has clear limits - the guarantee terms that override those limits (if any) are not documented in the publicly accessible policy pages reviewed for this article.

View the current FeelGood GLP-1 offer (official FeelGood page)

FeelGood GLP-1 Cancellation Policy: What You Need to Know

FeelGood is a subscription. That means the cancellation terms aren't fine print you can skip - they're something you need to have read before your card is charged. Here's exactly what the published policy says.

You can cancel any time for any reason. The method is email: send your cancellation request to support@feelgoodmeds.com with your name and the email associated with your account. The brand also notes you may be able to cancel through your online account portal if that option is available. The 72-hour rule is the one that catches people: your cancellation request must arrive at least 72 hours before your billing date. Miss that window and you'll be charged for the next cycle, with the cancellation effective on the subsequent billing period. After cancellation, service continues through the end of your paid period.

The brand's refund policy also confirms that bundle or multi-month plan refunds, if eligible, are prorated based on the number of shipments received and standard (non-bundled) monthly pricing - not the bundle rate you paid.

For California residents: California's Auto-Renewal Law (Business and Professions Code §17600) and the federal ROSCA (15 USC §8401) require that auto-renewal terms be clearly disclosed before you agree to a subscription. FeelGood's subscription nature means these protections apply to California buyers. Verify that you receive a clear disclosure of renewal terms at the point of enrollment.

Buyer Takeaway: Set a calendar reminder for 72+ hours before your expected billing date the moment you enroll. That's your cancellation window. The policy is reasonable and standard for subscription telehealth - just don't miss the notice window.

What Consumers Should Know About GLP-1 Evidence and FeelGood's Brand-Stated Outcome Claims

There are two separate issues consumers should not confuse: the clinical evidence for FDA-approved GLP-1 medications in appropriate patients, and FeelGood's brand-stated outcome claims for its own telehealth program. They are not the same thing, and this section covers both distinctly.

On the first question, the clinical evidence base for GLP-1 receptor agonists is substantial and well-documented across multiple independent research organizations. Peer-reviewed research published in journals including the New England Journal of Medicine has demonstrated statistically significant weight loss outcomes with semaglutide and tirzepatide in large randomized controlled trials involving thousands of participants tracked over periods of 68 weeks or longer. The National Institute of Diabetes and Digestive and Kidney Diseases, the Endocrine Society, and major obesity medicine organizations recognize GLP-1 receptor agonists as evidence-based interventions for obesity management in appropriately selected adult patients. This isn't a marginal supplement category or an emerging fringe treatment - it's a class of prescription medications with a robust clinical trial data package that informed medical consensus supports for weight management in qualifying patients.

On the second question - FeelGood specifically - FeelGood reports that patients on its GLP-1 program lose 15-20% of body weight on average; this is a brand-stated figure, not independently audited by this publication, and individual results vary. The figure hasn't been verified through a published peer-reviewed study specific to FeelGood's patient population. Individual results vary, and outcomes on compounded GLP-1 preparations may differ from outcomes documented in clinical trials using brand-name FDA-approved formulations. The brand's own site notes: "Results may vary."

FeelGood displays patient testimonials and before-and-after examples on its official website. The official site displays examples of individual patients reporting different amounts of weight loss over different time periods. These testimonials are brand-published individual experiences. They are not independently verified by this publication, may not represent typical outcomes, and should not be interpreted as guarantees of weight loss, medication eligibility, side-effect profile, prescription approval, or health outcomes. Individual results vary. Consumers should discuss realistic expectations, risks, and alternatives with a licensed healthcare provider before starting any prescription weight-management medication.

Quick Answer: Does GLP-1 medication work for weight loss?

GLP-1 receptor agonists as a drug class have substantial clinical trial evidence supporting significant weight loss outcomes, with peer-reviewed research demonstrating statistically meaningful reductions in body weight in large randomized controlled trials. FeelGood reports that patients on its GLP-1 program lose 15-20% of body weight on average; this is a brand-stated figure, not independently audited by this publication, and individual results vary. Compounded GLP-1 medications occupy a different regulatory category than FDA-approved brand-name drugs, and individual results vary depending on adherence, dosage, diet, activity, and individual physiology.

Buyer Takeaway: FDA-approved GLP-1 medications have well-documented clinical evidence for their specific approved indications in appropriately selected patients - that's what FDA approval means by definition. That body of evidence does not independently validate FeelGood's compounded formulations, specific dosing, or individual outcomes, which haven't been evaluated by the FDA. The meaningful question for you personally is whether you're a clinical candidate for GLP-1 treatment - that's a conversation with a licensed provider, which is exactly what the enrollment process provides.

What the Evidence Says About GLP-1 Medications: An Honest Summary

GLP-1 receptor agonists work through a mechanism that's been well-characterized in peer-reviewed medical literature and forms the basis for the clinical evidence that's made this drug class one of the most discussed pharmacological developments in obesity medicine in a generation. GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone secreted by enteroendocrine L-cells in the small intestine in response to food intake, where it signals satiety to the brain through hypothalamic receptor binding, slows gastric emptying to prolong the feeling of fullness, and modulates the release of insulin and glucagon in a glucose-dependent manner that helps stabilize post-meal blood sugar without the hypoglycemia risk associated with older drug classes. Pharmaceutical GLP-1 analogs work by mimicking and extending the activity of this natural hormone - producing the appetite-suppressing and metabolic effects at sustained concentrations that the natural hormone, which is rapidly degraded by the enzyme DPP-4, can't maintain on its own.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Center for Complementary and Integrative Health (NCCIH) both acknowledge the evidence base for GLP-1 receptor agonists in obesity medicine as part of the broader federal research and clinical guidance infrastructure. Cochrane-standard systematic reviews have examined the randomized controlled trial data across multiple GLP-1 medications, and the weight of the published evidence supports the conclusion that in properly selected patients, GLP-1 receptor agonists produce clinically meaningful weight loss that exceeds what diet and exercise alone typically achieve without pharmacological support. Side effects - primarily gastrointestinal (nausea, vomiting, constipation, and abdominal discomfort) - are well-documented in clinical trial populations and are typically most pronounced during the initial titration phase before the body adapts to rising drug concentrations, which is why the standard-of-care approach involves gradual dose escalation over several weeks or months rather than starting at full therapeutic dose.

What the evidence doesn't resolve is whether compounded GLP-1 preparations have equivalent efficacy and safety profiles to their brand-name FDA-approved counterparts. Compounding pharmacies operate under different regulatory oversight. Quality, potency, and sterility standards vary. The FDA has issued guidance on this issue - buyers using compounded GLP-1 medications should understand they're using a product in a different regulatory category than the medications studied in the major clinical trials.

None of this is meant to suggest compounded GLP-1 programs are ineffective or unsafe. Millions of Americans access compounded medications for cost and access reasons, and they're prepared by licensed facilities under applicable pharmacy law. But informed consent means understanding the difference - and a good provider on a platform like FeelGood should be having this conversation with you during your intake evaluation.

Buyer Takeaway: The clinical case for GLP-1 as a drug class is solid. The regulatory distinction between FDA-approved and compounded formulations is real and worth discussing with your provider. Asking about the specific compounding pharmacy, its quality standards, and the drug preparation protocol is a reasonable and appropriate question before starting.

FeelGood GLP-1 vs. Other Telehealth GLP-1 Platforms: How the Pricing Compares

The telehealth GLP-1 space has expanded rapidly, and price is now the primary differentiator buyers use to compare programs. FeelGood advertises compounded injections at a starting price of $149/month, according to its published pricing. Pricing across GLP-1 telehealth and pharmacy channels changes frequently. Consumers comparing FeelGood with other options should review current costs, medication type, provider access, pharmacy fulfillment, refund terms, and whether the option involves compounded medication or an FDA-approved product - rather than relying on any static price comparison.

Beyond price, the meaningful comparison points are: what's included in the monthly fee (consultation, medication, shipping, support); the cancellation and refund policy terms (which vary significantly across platforms in ways that matter when you want to stop); the medical group and provider oversight structure (who's actually prescribing, and what their licensing and accountability framework looks like); compounding pharmacy quality credentials (whether the pharmacy is 503A or 503B registered, PCAB-accredited, or subject to additional third-party quality audits); and the platform's LegitScript or equivalent certification status. FeelGood's site displays a LegitScript verification reference, which consumers can verify directly at legitscript.com - a meaningful differentiator that not all telehealth GLP-1 platforms carry, because it requires demonstrating ongoing compliance with standards that the certification body actively monitors.

Brand-name FDA-approved GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) remain in a different price category entirely - typically $900 to $1,300+ per month without insurance, with coverage and prior authorization requirements that exclude many patients. The compounded telehealth route exists because that price gap is real and significant.

Buyer Takeaway: On price alone, FeelGood is competitive. The more important comparison variables are what you get for that price, what happens if you need to cancel, and whether the medical oversight structure meets your standard for informed clinical care. Those questions have answers - they just require you to ask them before enrolling, not after.

What You Need to Know About the FDA and Compounded GLP-1 Medications in 2026

Most telehealth GLP-1 reviews skip this section entirely. It's the one you most need to read before enrolling anywhere - not just FeelGood.

The compounded GLP-1 market expanded dramatically during a period when brand-name semaglutide and tirzepatide were on the FDA's official drug shortage list. When a drug is in shortage, federal law under sections 503A and 503B of the Food, Drug and Cosmetic Act permits licensed compounding pharmacies and outsourcing facilities to compound drugs that would otherwise be considered an unapproved copy of an FDA-approved product - an exemption that allowed the compounded GLP-1 telehealth industry to scale significantly between 2022 and 2024.

Here's what changed - and what it means for anyone enrolling in a compounded GLP-1 program today. This section reflects publicly available FDA information as of June 2026; consumers should verify current status at FDA.gov before making enrollment decisions.

Federal rules around compounding can change depending on drug availability, patient-specific medical need, pharmacy type, and FDA enforcement priorities. According to FDA's publicly available guidance, compounded drugs may be appropriate when a patient's medical need cannot be met by an FDA-approved drug or when an FDA-approved product is unavailable due to a drug shortage. Compounded drugs are not FDA-approved regardless of circumstances.

As of April 2026, the FDA formally proposed - in a Federal Register notice - removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list. A public comment period was open through June 2026. If that proposal is finalized, 503B outsourcing facilities lose the legal basis to compound these drugs at scale. Consumers should verify the current status of this proposal directly at FDA.gov before making any enrollment decision that depends on compounded GLP-1 availability.

For 503A state-licensed pharmacies - the pathway most telehealth platforms use for patient-specific prescriptions - a narrower legal framework applies. Under current FDA guidance, a 503A pharmacy can compound a GLP-1 medication for a specific patient only when the prescriber documents a "significant difference" - a genuine clinical reason why the compounded formulation serves that patient's specific medical need in a way the commercially available FDA-approved product cannot. That documentation requirement is not a formality. It's the legal basis for the prescription. Buyers should ask their assigned provider: what specific clinical justification will be documented for prescribing a compounded rather than FDA-approved GLP-1 for me? A provider who can't answer that clearly is worth pausing on.

It's also worth knowing that FDA enforcement in this space reaches the pharmacy level directly, not just telehealth platforms. In January 2026, the FDA issued a warning letter to a 503A compounding pharmacy specifically for GLP-1 product violations involving insanitary conditions and strength, quality, and purity noncompliance. This doesn't implicate FeelGood's specific pharmacy - which is not publicly identified in available documentation - but it reinforces why asking for the pharmacy name and requesting a Certificate of Analysis is a reasonable buyer protection step, not an excessive one.

What does this mean for you as a buyer considering a compounded GLP-1 program?

• The shortage-based legal exemption that underpinned widespread compounded semaglutide availability is no longer active for either 503A pharmacies or 503B outsourcing facilities

• Compounded GLP-1 programs operating today must navigate a legal framework that includes restrictions on compounding drugs that are commercially available drugs - meaning the compounding pharmacy's specific formulation, documentation, and prescriber individualization process matters for legal compliance

• The FDA still permits compounding under 503A for individual patient-specific prescriptions that involve a prescriber-documented "significant difference" from the commercially available product - but that requires specific clinical justification, not just a standard intake form

• Availability of specific compounded GLP-1 formulations may be affected by FDA enforcement actions, pharmacy-specific compliance status, and ongoing regulatory developments in this space

None of this means compounded GLP-1 programs are operating illegally. It means the regulatory framework is specific, documented, and being actively enforced - and buyers who understand what violations look like are better positioned to choose a platform that avoids them.

What FDA's Public Guidance on Compounded GLP-1 Products Says - and How Consumers Can Use It as a Due-Diligence Framework

FDA has publicly identified concerns involving unapproved and compounded GLP-1 products. The documented concern categories include: claims implying compounded GLP-1 products are equivalent to FDA-approved drugs; unsubstantiated claims about the safety or effectiveness of compounded formulations; and marketing that obscures which entity actually compounds the medication. These are FDA's publicly stated consumer-protection areas of concern - not findings about any individual platform.

That third violation is worth pausing on. A platform that says "our medication" while sourcing from a third-party compounder - and doesn't make that clear - was specifically cited as a violation type. FeelGood's published Terms of Use and OpenLoop Healthcare Partners PC telehealth consent are explicit that FeelGood doesn't provide medical services, prescriptions are issued by independent licensed providers, and medication is fulfilled by a third-party pharmacy. These public disclosures reflect the type of transparency that is useful for consumer due diligence.

The same week those letters went out, A major telehealth platform announced a partnership with a brand-name GLP-1 manufacturer in early 2026, agreeing to shift toward branded medications and pull back most compounded GLP-1 advertising.

Here are four consumer due-diligence questions that FDA's publicly stated concerns make relevant for any buyer evaluating a compounded GLP-1 platform:

• Does the platform's marketing imply equivalence to FDA-approved drugs? FeelGood's published materials include the disclaimer "Results may vary" and the OpenLoop consent explicitly states FDA doesn't approve compounded products. These public disclosures are useful for consumer due diligence, but do not independently establish legal compliance, pharmacy compliance, medication quality, or clinical appropriateness.

• Does the platform disclose which entity actually compounds your medication? FeelGood's three-entity structure - platform, medical group, third-party pharmacy - is publicly documented. The specific pharmacy name isn't identified in public materials; ask support@feelgoodmeds.com for it before you enroll.

• Are outcome claims substantiated or clearly attributed as brand-stated? FeelGood's published metrics carry "brand-stated" and "Results may vary" qualifiers. This article adds "not independently audited" to every figure. That reflects the type of transparent attribution that FDA's publicly stated concerns around compounded GLP-1 marketing specifically address.

• Is LegitScript verification current and active? FeelGood's seal is verifiable at legitscript.com. In a category where FDA has publicly identified compounded GLP-1 concerns, a LegitScript verification reference is worth independently verifying - check current status at legitscript.com before enrollment.

Buyer Takeaway: FDA has publicly identified concerns involving unapproved and compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent compounded products, adverse-event reports, semaglutide salt forms, and illegal online sales. This article uses FDA's public guidance as a consumer due-diligence framework and does not determine whether any specific FeelGood prescription, provider, pharmacy, or program complies with federal or state law. Use the four questions above for FeelGood and for any platform you're comparing it against.

Is FeelGood GLP-1 Legit? Verification Checklist for Cautious Buyers

It's one of the most-searched questions about any telehealth service, and it's the right question to ask. Here's what this article can confirm from publicly available documentation, and what buyers should verify independently before enrolling.

What can be confirmed from public documentation:

• A LegitScript verification reference is displayed on the official FeelGood website; consumers should verify current status directly at legitscript.com before enrollment

• Medical group on record - OpenLoop Healthcare Partners, PC - is an established telehealth medical group with publicly posted telehealth consent, SOC 2 certification (via Vanta), and a verifiable address at 317 6th Ave Ste 400, Des Moines, IA 50309

• Refund policy, Terms of Use, and telehealth consent are all publicly accessible on the official website

• Cancellation process is documented and clear

• iOS and Android apps are publicly available in app stores

• Contact information for support is published and functional

• "Prescription medications require a virtual consultation and approval by a licensed healthcare provider" - brand disclaimer is present and accurate

What requires direct buyer verification:

• Specific terms of the "Weight Loss Money Back Guarantee" - contact support@feelgoodmeds.com before enrolling

• Name and accreditation status of the specific compounding pharmacy fulfilling your prescription

• Exact medication name, dosage, and titration protocol for your program tier

• What is bundled vs. billed separately at your specific tier

• "USA Made" claim - confirm specific manufacturing origin of compounded medication with support

Quick Answer: What's the difference between a 503A and 503B compounding pharmacy?

503A pharmacies compound medications for specific individual patients based on a valid prescription from a licensed prescriber. They operate under state pharmacy board oversight. 503B facilities are outsourcing facilities that compound drugs in larger quantities for healthcare facilities - they're subject to additional federal FDA oversight and voluntary inspection, which generally means higher manufacturing quality standards. When a compounded GLP-1 program uses a 503B pharmacy, that typically signals stronger quality controls. Knowing which type FeelGood's partner pharmacy is - and whether it holds any third-party accreditation such as PCAB certification - is one of the most useful questions you can ask before enrolling. Ask FeelGood support directly for the pharmacy name and type before your first billing cycle.

Buyer Takeaway: The foundational legitimacy indicators - LegitScript, publicly accessible legal documentation, an established and independently verified medical group - are present and verifiable. The specific program details that matter most to your personal decision require a direct conversation with FeelGood before you commit to a subscription cycle.

Who Is a Good Candidate for GLP-1 Weight Loss Programs?

GLP-1 medications are prescription drugs, which means a licensed provider determines whether you qualify - not a marketing quiz and not this article. That said, there's useful general context from published clinical guidelines worth knowing before you fill out an intake form.

Published clinical guidelines from organizations including the American Society of Metabolic and Bariatric Surgery and the Obesity Medicine Association have identified GLP-1 receptor agonists as appropriate pharmacological interventions in patients with a BMI of 30 or above (classified as obesity), or BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea - the same criteria framework used by the FDA in evaluating GLP-1 medications for their obesity management indications. These are the clinical thresholds that inform prescribing decisions; your individual eligibility depends on your specific health profile and the clinical judgment of your assigned provider, who has access to more information than any eligibility quiz can capture.

GLP-1 medications aren't appropriate for everyone. Patients with a personal or family history of medullary thyroid carcinoma, patients with Multiple Endocrine Neoplasia syndrome type 2, patients who are pregnant or planning to become pregnant, and patients with certain gastrointestinal conditions may not be eligible. Drug interactions with other medications - particularly insulin, sulfonylureas, and other blood sugar-affecting drugs - require careful clinical management. Your FeelGood provider's job is to identify these factors and make an individualized clinical judgment.

Drug interaction note: GLP-1 receptor agonists may interact with nitrate-class medications, anticoagulants, and drugs for blood sugar management. Disclose all current medications to your provider during intake.

Buyer Takeaway: The eligibility question has a real answer - but only your provider can give it to you after reviewing your health history. The value of a telehealth platform like FeelGood is that it makes that conversation accessible, affordable, and fast. Don't skip the intake or misrepresent your health history to accelerate approval - that's both unsafe and a violation of the platform's Terms.

What Happens If FeelGood Isn't Right for You?

Not everyone who applies will be approved, and not everyone who gets approved will stay enrolled. Here are the most common exit scenarios - and what happens to your money in each one.

If a licensed provider reviews your intake and determines you're not clinically eligible for GLP-1 medication, your subscription is cancelled and a full refund is available since medication hasn't been ordered. That's the most buyer-friendly outcome if it turns out the program isn't right for you medically.

If you're approved, start the program, and then decide it's not for you after medication has been shipped - the refund policy limits your options. Per the published policy, once medication is ordered, it can't be returned and fees aren't refundable. You can cancel the subscription (email support@feelgoodmeds.com; 72-hour notice before billing date), and your access continues through the end of the current paid period.

If you experience side effects, the brand's lander FAQ mentions side effect support as part of the enrollment package. Contacting your provider through the platform is the appropriate first step - not cancellation. Dose adjustments and titration protocol changes are normal parts of GLP-1 treatment management and can often address tolerability issues.

Buyer Takeaway: FeelGood's program structure rewards buyers who do their homework before the first billing cycle. Understand the refund terms, understand the cancellation window, and make sure you've asked about the guarantee terms before your card is charged.

How to Read FeelGood's Marketing Language: A Buyer's Translation Guide

Marketing language on telehealth platforms can create expectations that don't survive contact with the fine print. Here's a quick translation guide for the specific phrases FeelGood uses on its official website, so you know what you're actually buying.

"Fat loss made easy with personalized GLP-1 medication" - means the enrollment process is digital and convenient (no office visit, no insurance required). It doesn't mean weight loss is easy. GLP-1 medications require consistent adherence, may require lifestyle modifications, and come with a titration period during which side effects are common.

"Lose pounds of fat every week" - brand positioning language describing the potential outcome the program is designed to support. It doesn't describe a guaranteed weekly loss rate. Individual response to GLP-1 medication varies significantly based on starting weight, dosage, adherence, diet, and physiology.

"No membership or hidden fees - Everything you need is included" - describes the brand's pricing model intent. Verify at checkout that your specific tier bundles consultation, medication, and shipping into the stated monthly price without add-ons.

"100k+ Patients Agree - When nothing else worked, FeelGood did" - brand-reported patient count and brand-curated testimonial framing. Customer ratings and testimonials are brand-reported, not independently audited. Individual experiences vary.

"On average, patients on our GLP-1 program lose 15-20% of their body weight" - brand-stated average. Not independently verified, not published in a peer-reviewed study specific to FeelGood's patient population. Individual results vary.

"Excellent 4.8 out of 5" - brand-reported rating. Source of reviews and verification methodology not disclosed in publicly available documentation. Buyers can verify by searching independently for FeelGood reviews on third-party platforms.

Buyer Takeaway: None of the marketing language above is inherently deceptive - it's standard promotional positioning for a competitive telehealth GLP-1 market. But there's a difference between what the brand says it's designed to deliver and what any individual buyer should expect. That gap is where informed decision-making lives.

FeelGood GLP-1 Side Effects: What Buyers Should Know

GLP-1 receptor agonists have a well-documented side effect profile that's been characterized across multiple large clinical trials. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These occur most frequently during the initial titration phase, as dosage is increased from a starting level toward a therapeutic target. For most patients in clinical trials, GI side effects were described as mild-to-moderate and transient.

Serious adverse events are less common but documented: pancreatitis, gallbladder disease, hypoglycemia (particularly in patients on concomitant diabetes medications), and a boxed warning regarding medullary thyroid carcinoma risk in rodent studies - a finding whose clinical significance in humans at therapeutic doses remains under study. These are reasons that clinical evaluation before starting is not optional, and why full disclosure of your medical history during intake isn't just a formality.

There are two specific safety risks with compounded injectable GLP-1s that go beyond standard medication side effects, and both have been the subject of public regulatory and legal attention in 2025-2026.

The first is dosing errors. FDA-approved brand-name injectable GLP-1 medications typically come in pre-filled auto-injector pens with preset doses. Compounded injectable GLP-1s typically come in multi-dose vials - you draw the dose yourself using a syringe. The FDA has received adverse event reports, some requiring hospitalization, involving dosing errors in which patients administered five to twenty times their intended dose due to unfamiliarity with vial-to-syringe measurement and confusion between units (milligrams vs. milliliters vs. "units") as contributing factors.

The second is product quality and impurity risk. In litigation filed in early 2026, a major GLP-1 manufacturer alleged that testing of compounded injectable semaglutide products found impurity levels as high as 86%, with compounded oral formulations containing impurities as high as 75%. The allegation states that even small amounts of these impurities can cause unwanted immune responses including anaphylactic shock. These are allegations in pending litigation - not independent FDA findings about FeelGood's specific program or pharmacy. However, FDA has separately identified product quality as a documented concern category for compounded GLP-1 products generally, including contamination and variable potency. Buyers should ask for the specific compounding pharmacy name, confirm whether any FDA enforcement actions have been issued to that pharmacy, and ask whether a Certificate of Analysis (CoA) for sterility, potency, and endotoxin testing is available for their specific medication batch before their first dose.

This isn't a reason to avoid compounded injectable GLP-1s - it's a reason to make sure your provider explains exactly how to measure and administer your specific dose before your first injection, and to confirm that the compounding pharmacy provides appropriate syringe sizing for your prescribed dose. Ask these questions before your first shipment arrives, not after.

The FDA has also warned that some compounded semaglutide products may use salt forms - semaglutide sodium or semaglutide acetate - which are chemically different from the active ingredient in FDA-approved semaglutide products. According to the FDA, there is no known lawful basis for using these salt forms in compounding, and the FDA is not aware of evidence that they have the same chemical and pharmacological properties as base-form semaglutide. Ask your provider or FeelGood support whether your specific compounded product uses the base form of semaglutide - not a salt form - before you start.

This publication is not providing medical advice about side effects - your provider is. Ask your provider during intake: what should I expect during titration, when should I contact you, and what would warrant stopping the medication?

Buyer Takeaway: Compounded injectable GLP-1s require self-measurement from a vial - a meaningfully different administration process from brand-name pre-filled auto-injectors. The FDA has documented serious dosing errors with compounded injectables. Get explicit dosing and measurement guidance from your provider before your first injection. Also ask whether your specific product uses base-form semaglutide, not a salt form. Ask those questions of your provider before your first dose - they have straightforward answers.

FeelGood GLP-1 Support: What 24/7 Access Actually Means

The brand states 24/7 access to a dedicated team of specialists is included with the subscription, along with unlimited appointments and messaging. That's a meaningful differentiator compared to traditional healthcare - where getting a question answered often means scheduling an appointment days out, leaving a phone message, and waiting for a callback during business hours that may not align with when you're experiencing a side effect or need a dose adjustment conversation.

What the brand doesn't detail in publicly accessible documentation is the specific response time commitment, whether 24/7 access means live human support at all hours or message queue support reviewed within a defined window, and whether the specialists you're reaching are licensed clinicians or support coordinators. These are reasonable questions to ask before enrolling - particularly because GLP-1 side effect management can be time-sensitive and the titration period, when nausea and GI side effects are most common, is exactly when you most need responsive clinical guidance rather than a next-business-day callback.

The platform also includes a mobile app for iOS and Google Play, which serves as the primary interface for messaging, appointments, and care coordination. The patient portal is accessible at feelgoodmeds.portal.tellescope.com.

Buyer Takeaway: Brand-stated 24/7 support is a real benefit for a prescription medication program. Get clarity on what that means in practice - response time expectations and the type of support available after hours - before you're trying to manage a side effect at 2am.

FeelGood GLP-1 HSA/FSA Eligibility: What the Brand States

FeelGood states that its programs are HSA/FSA eligible. That's a meaningful feature for buyers who have pre-tax health savings account or flexible spending account funds available - it effectively reduces the out-of-pocket cost by the buyer's marginal tax rate.

HSA/FSA eligibility for prescription medications prescribed by licensed providers is generally established under IRS guidelines when the cost is for a qualified medical expense. Telehealth consultation fees for prescription services typically qualify under these guidelines. Buyers should confirm with their HSA/FSA administrator that FeelGood's program qualifies under their specific plan, as administrator interpretations vary. The brand's claim of eligibility is reasonable given the prescription nature of the service, but FeelGood's characterization doesn't override your plan administrator's rules.

Buyer Takeaway: If you have HSA/FSA funds, ask FeelGood support for documentation needed for HSA/FSA reimbursement before your first charge. Confirming with your plan administrator in advance saves you a reimbursement dispute later.

FeelGood GLP-1 App: Is It Worth Using?

FeelGood has a mobile app on iOS and Android - "Total care. In your pocket," as the brand puts it. For a subscription telehealth service, that matters more than it sounds. Your care management, provider messaging, and support access all run through that app.

The app provides access to the patient portal, messaging with support and providers, and care management tools. For a subscription-based telehealth service where ongoing provider communication is central to the treatment protocol, having a dedicated mobile app rather than a browser-only portal is a real usability advantage. The app's ratings and review count in app stores are publicly verifiable by searching "FeelGood" in the iOS App Store or Google Play.

Buyer Takeaway: If you're enrolling in a subscription GLP-1 program, you'll be using whatever communication tool the platform provides regularly - for check-ins, side effect reporting, dose adjustment requests, and support questions. A dedicated app is a better experience than email for this level of ongoing engagement. Download it before your first appointment, not after.

Questions About FeelGood GLP-1 Worth Asking Before You Start

These aren't hypothetical questions. Every one of them has an answer - and you should get that answer in writing from FeelGood before you authorize the first charge. Reach out at support@feelgoodmeds.com or through the patient portal.

• What are the exact terms of the Weight Loss Money Back Guarantee, and how does a patient claim it?

• What is the name and accreditation status of the compounding pharmacy that will fill my prescription?

• What specific medication and starting dosage will I receive at the $149/month tier?

• What is the titration protocol - how does dosage increase over time and who manages that process?

• Is the $149/month price inclusive of consultation, medication, and shipping, or are any components billed separately?

• What is the response time commitment for 24/7 support - live human or message queue?

• Can I confirm "USA Made" refers to where my specific compounded medication is prepared?

• What are the specific cancellation steps if I use the online account portal option vs. email?

• Was FeelGood's compounding pharmacy ever subject to FDA inspection, warning letter, or enforcement action? Ask support@feelgoodmeds.com for the pharmacy name and state license number so you can verify independently.

• How does FeelGood's prescribing protocol document clinical individualization - the "significant difference" from commercially available products required under current 503A post-shortage guidance?

Buyer Takeaway: A telehealth platform that's genuinely confident in its program will answer all of these questions clearly and in writing. If any of these questions get evasive responses, that's information worth having before you subscribe.

FeelGood GLP-1 Buyer Verification Checklist: 20 Questions to Ask Before Enrollment

These aren't hypothetical questions - every one has a specific answer that FeelGood support at support@feelgoodmeds.com should be able to provide in writing before you authorize your first charge.

• Confirm the current starting price for your specific program tier before checkout.

• Confirm whether the monthly price includes the compounded medication itself - not just the platform access or consultation.

• Confirm whether consultation fees, provider review fees, or lab work are included or billed separately.

• Confirm whether shipping is free for your selected program and location.

• Confirm the exact medication name before starting.

• Confirm whether the medication is compounded or FDA-approved.

• Confirm the compounding pharmacy name and ask for their state license number.

• Confirm whether the pharmacy is a 503A state-licensed pharmacy or a 503B outsourcing facility.

• Ask your assigned provider what specific "significant difference" from the commercially available FDA-approved product will be documented in your prescription - this is the legal basis for a 503A compounded prescription under current FDA guidance, and a provider should answer clearly.

• Confirm the current status of FDA's June 2026 503B bulks list proposal and what it means for your program's pharmacy and medication source - verify at FDA.gov before your first billing cycle.

• Confirm whether the medication uses semaglutide base form rather than a salt form, if semaglutide is prescribed.

• Ask whether a Certificate of Analysis (CoA) is available for your specific medication batch, confirming sterility, potency, and endotoxin testing - a reputable compounding pharmacy should provide this on request.

• If considering the Compounded Tablets tier: ask your assigned provider directly about the bioavailability and absorption pathway for compounded oral GLP-1 peptide medications, and what clinical evidence supports the specific oral formulation being prescribed.

• Confirm dosing instructions in writing before first use - particularly how to measure injectable doses if vials and syringes are used.

• Confirm storage and shipping temperature requirements for your medication.

• Confirm the exact terms of the "Weight Loss Money Back Guarantee" in writing before enrollment, including what qualifies, what documentation is required, and how it interacts with the published refund policy.

• Confirm cancellation steps and the notice window required before your billing date.

• Confirm expected provider follow-up and titration protocol.

• Confirm how side effects should be reported and what response time to expect.

• Confirm whether 24/7 support means live clinical access, customer-service messaging, provider messaging, or another model.

• Confirm your specific data privacy questions in writing before sharing health information.

• Confirm the LegitScript verification status directly at legitscript.com before enrollment.

• Confirm whether any current medications, health conditions, pregnancy status, or family medical history may affect your eligibility - ask your assigned provider during intake.

• Confirm the HSA/FSA eligibility of your specific program with your plan administrator before using those funds.

Buyer Takeaway: A telehealth platform confident in its program will answer all 20 of these questions clearly and in writing. Get the answers before your first charge - not after.

How Does FeelGood Compare to Traditional Weight Loss Options?

The reason GLP-1 telehealth platforms exist is the same reason patients are using them at scale: traditional routes to prescription weight loss medication are expensive, slow, often unavailable, and structured around insurance systems that have historically classified obesity treatment as an elective rather than a chronic metabolic condition requiring clinical management - a classification that major professional societies have spent years working to overturn. Without insurance coverage, FDA-approved brand-name GLP-1 medications can run significantly higher at retail - often $900 to $1,300+ per month without insurance - placing evidence-based pharmacotherapy out of reach for the majority of patients who could clinically benefit. With insurance, prior authorization requirements and step-therapy protocols create multi-month delays even for patients who clearly meet clinical eligibility criteria.

Telehealth platforms like FeelGood offer a different tradeoff: lower cost, faster access, no office visit, and no insurance requirement. The tradeoff is that you're receiving compounded rather than brand-name FDA-approved medication, and your clinical relationship is entirely digital. Whether those tradeoffs are right for a given buyer depends entirely on their clinical situation, financial circumstances, and personal priorities - not on a press release.

Traditional weight loss interventions like very-low-calorie diets, behavioral modification programs, and over-the-counter supplements have a substantially weaker evidence base than prescription GLP-1 medications for sustained, clinically significant weight loss that persists beyond the active intervention period - a distinction that matters when you're evaluating whether a monthly subscription to a medication program is a better long-term value than another round of a protocol you've already tried and discontinued. That's not a brand claim; it reflects the current consensus in peer-reviewed obesity medicine literature and the clinical guideline positions of major endocrinology and bariatric medicine professional societies. Whether that evidence base justifies the cost and the compounded-medication tradeoffs of FeelGood's specific program is a decision only you and your provider can make.

One comparison that's increasingly relevant in mid-2026: Walgreens and other retail pharmacy platforms are now advertising FDA-approved oral GLP-1 medications at starting prices that overlap with compounded program prices, according to publicly available pharmacy pricing as of June 2026. That's the same entry price as FeelGood's compounded injections - but for an FDA-approved brand-name drug rather than a compounded preparation. Buyers in the market for compounded GLP-1 programs should be aware that the FDA-approved oral option exists at a comparable starting price point, understand how it differs (FDA-approved vs. compounded, oral vs. injectable, retail pharmacy vs. telehealth platform, self-pay promotional pricing vs. subscription), and make that comparison part of their decision-making before enrolling anywhere.

Buyer Takeaway: FeelGood's value proposition is real: clinician-supervised access to compounded GLP-1 through a platform designed around digital convenience, without insurance requirements or office visits. Whether it's right for your specific situation - vs. an FDA-approved compounded or brand-name alternative - is a clinical and personal decision. The enrollment process is how you get the clinical question answered; this article is how you get the comparison context first.

View the current FeelGood GLP-1 offer (official FeelGood page)

FeelGood GLP-1 FAQ: 15 Questions Buyers Ask Most

What is FeelGood GLP-1 and how does it work?

FeelGood is a telehealth subscription platform that connects patients with licensed medical providers for evaluation and, when clinically appropriate, access to compounded GLP-1 weight loss medication. The process starts with an online intake evaluation reviewed by a licensed provider from OpenLoop Healthcare Partners, PC. If a prescription is issued, the compounded medication is shipped from a licensed third-party pharmacy directly to your home. No in-person office visit or insurance is required. Compounded injections start at $149 per month according to the brand's published pricing as of June 2026.

Is FeelGood a legitimate company?

FeelGood carries LegitScript verification - a credential that distinguishes compliant online healthcare and pharmacy platforms from illegitimate operations. The medical group providing clinical services, OpenLoop Healthcare Partners, PC, is a publicly documented telehealth entity with its own published consent forms, SOC 2 certification, and verifiable address. Refund and cancellation policies are publicly posted. These are the foundational legitimacy markers buyers can verify independently. Beyond verifiable credentials, buyers should confirm program-specific terms with support before enrolling.

Are FeelGood's GLP-1 medications FDA-approved?

No. FeelGood's compounded GLP-1 injections and tablets are compounded by a licensed third-party pharmacy and are not FDA-approved. Per the telehealth consent published by OpenLoop Healthcare Partners, PC, the FDA does not approve, review, or evaluate compounded products for safety, effectiveness, or quality. Compounding pharmacies operate under state and federal pharmaceutical regulations, but compounded medications are in a distinct regulatory category from brand-name FDA-approved GLP-1 drugs. Buyers should discuss this distinction with their assigned provider during intake.

What happened to the FDA GLP-1 shortage and how does it affect compounded programs?

The FDA shortage determinations that supported widespread compounded semaglutide and tirzepatide availability resolved in 2025. According to the FDA's official guidance (updated April 2026 at fda.gov), the semaglutide injection shortage was resolved on February 21, 2025, and the transitional exemption windows for compounders operating under the shortage exemption subsequently ended - for 503A pharmacies by April 22, 2025, and for 503B outsourcing facilities by May 22, 2025. Tirzepatide shortage resolution followed a similar timeline. As of April 2026, neither semaglutide nor tirzepatide appears on the FDA's drug shortage list or 503B bulks list. Compounded GLP-1 programs operating in 2026 must navigate the post-shortage legal framework, which includes restrictions on compounding drugs that are commercially available drugs under sections 503A and 503B of the FD&C Act. Buyers should ask any compounded GLP-1 platform about their specific compounding pharmacy's legal compliance framework under current FDA guidance.

How much does FeelGood cost per month?

According to published pricing on the official FeelGood website as of June 2026: compounded injections start at $149/month, compounded tablets start at $249/month, and original injections start at $1,999/month with noted limited availability. These are "starting at" figures - actual cost may vary by dosage and program tier. Free shipping is brand-stated. Buyers should verify the all-in price for their specific program at checkout before completing enrollment.

Can I cancel FeelGood anytime?

Yes. Per the published Cancellation Policy at feelgoodmeds.com/refund-policy, you can cancel any time for any reason by emailing support@feelgoodmeds.com. The critical detail: cancellation requests must be received at least 72 hours before your billing date. If you miss that window, you'll be charged for the next cycle, with cancellation effective on the subsequent billing period after that. After cancellation, service continues through the end of your paid period.

Does FeelGood accept HSA/FSA?

Yes, according to the brand's published information. FeelGood states HSA/FSA eligibility on its official website. Buyers should confirm with their specific HSA/FSA plan administrator before using those funds, as administrator interpretations of qualified medical expenses vary. Requesting documentation from FeelGood support for HSA/FSA submission before your first charge is advisable.

Is there a money-back guarantee?

The brand's lander prominently displays "Weight Loss Money Back Guarantee." The published refund policy limits refunds primarily to situations where medication has not yet been ordered - including medical disqualification by a licensed provider. Once medication is ordered, refunds are generally not available. Buyers should contact support@feelgoodmeds.com before enrolling to confirm the specific terms and eligibility requirements of any weight loss guarantee that may apply to their tier.

Do I need health insurance to use FeelGood?

No. FeelGood explicitly states "no insurance required" on its official website. The program is priced as a direct-pay subscription service. HSA/FSA funds can be used where plan-eligible. Insurance coverage for the service is not claimed or required for enrollment.

Who prescribes the medication through FeelGood?

Prescriptions are issued by licensed healthcare providers employed or contracted by OpenLoop Healthcare Partners, PC, the affiliated medical group. FeelGood itself does not provide medical services or prescribe medication. The provider makes an independent clinical judgment about eligibility and appropriate treatment. A prescription is not guaranteed - it depends on your intake evaluation results and provider assessment.

How long does it take to get started with FeelGood?

Per the brand's published FAQ, the enrollment process is designed to be fast. Specific timeline details - from intake submission to provider review to medication shipment - aren't documented in the publicly available materials reviewed for this article. Buyers should ask support for a realistic expected timeline before enrolling, particularly if they have a time-sensitive start date in mind.

What are the side effects of GLP-1 medications?

The most commonly reported side effects of GLP-1 receptor agonists, documented across multiple large randomized controlled clinical trials enrolling thousands of participants, are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, all of which are most commonly reported during the initial titration phase when dosage is being escalated from a low starting point toward a therapeutic target and the body is still adapting to the mechanism of action. These side effects typically diminish as the body adjusts to the medication. Serious adverse events including pancreatitis and gallbladder disease have been reported at lower rates across clinical trial populations. GLP-1 medications carry a prescribing warning regarding medullary thyroid carcinoma risk observed in rodent studies - a finding whose clinical significance in humans at therapeutic doses continues to be monitored in post-market surveillance. Buyers should discuss their personal medical history and risk factors with their FeelGood provider during intake.

What happens if my FeelGood provider says I'm not eligible?

If a licensed provider determines you're medically ineligible for GLP-1 medication before your medication is ordered, your subscription is cancelled and a full refund is available per the published refund policy. That's a favorable outcome compared to being charged for a service you can't receive. Buyers disqualified at intake receive a full refund - that's explicitly documented in FeelGood's published terms.

Does FeelGood ship free?

Yes, according to the brand's published information. Free shipping is stated on the official FeelGood website and in promotional materials. Buyers should confirm that free shipping applies to their specific program tier and geographic location at checkout.

What is the FDA's June 2026 compounding proposal and how does it affect FeelGood?

In April 2026, the FDA published a formal proposal in the Federal Register to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list, with a public comment period open through June 2026. If finalized, this means 503B outsourcing facilities - which compound drugs in larger batches for healthcare facilities and telehealth platforms - would lose the legal basis to compound these specific GLP-1 medications at scale. The 503A pathway for patient-specific compounding by state-licensed pharmacies remains available under a narrower framework, requiring that the prescriber document a "significant difference" justifying why the compounded version meets the specific patient's medical need in a way the FDA-approved product cannot. Consumers should verify the current status of this proposal at FDA.gov before enrolling in any compounded GLP-1 program, and ask their assigned provider which compounding pathway applies to their prescription and what specific clinical justification will be documented.

What data privacy questions should consumers ask before enrolling in FeelGood?

Because GLP-1 telehealth services involve sharing sensitive health information with a platform, a licensed medical group, and a compounding pharmacy, data privacy is a legitimate due-diligence topic. Consumers should review FeelGood's privacy policy and the OpenLoop Healthcare Partners, PC telehealth consent at openloophealth.com/telehealth-consent. Data-privacy questions can be directed in writing to support@feelgoodmeds.com before enrollment.

What is a Certificate of Analysis (CoA) and why should compounded GLP-1 buyers ask for one?

A Certificate of Analysis is a document from a compounding pharmacy confirming that a specific medication batch has been tested for sterility, potency, and endotoxin levels. In the context of compounded GLP-1 medications, a CoA provides the buyer with evidence that the specific batch they received meets quality standards - including that the active ingredient is present at the stated concentration and that the product is free of harmful contaminants. Because compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before marketing, a CoA from the compounding pharmacy represents one of the primary quality assurance mechanisms available to buyers. Reputable compounding pharmacies should be willing to provide CoA documentation upon request. Ask FeelGood support for the pharmacy name and ask the pharmacy directly whether a CoA is available for your specific medication batch before your first injection.

Are there specific safety risks with compounded injectable GLP-1 medications compared to brand-name options?

Yes - and the FDA has issued dedicated guidance about one in particular. FDA-approved brand-name injectable GLP-1 medications typically come in pre-filled auto-injector pens with preset doses. Compounded injectable GLP-1s typically come in multi-dose vials requiring the patient to draw and measure their own dose with a syringe. The FDA has received adverse event reports, some requiring hospitalization, involving dosing errors in which patients administered five to twenty times their intended dose, due to unfamiliarity with vial-to-syringe measurement and confusion between units. And the FDA has warned that some compounded semaglutide products may use salt forms - semaglutide sodium or semaglutide acetate - that are chemically different from the active ingredient in FDA-approved products and have no known lawful basis for use in compounding. Ask your provider for explicit dosing guidance and confirm the API form before your first injection.

Was FeelGood among the companies that received FDA GLP-1 enforcement letters in 2026?

Based on publicly available information as of June 2026, This article does not state that FeelGood has or has not received any specific FDA communication. Consumers should rely on FDA.gov, FeelGood support, and their licensed provider for current regulatory information, regarding misleading compounded GLP-1 marketing. The FDA's enforcement action targeted platforms making claims implying compounded products are equivalent to FDA-approved drugs, making unsubstantiated safety and efficacy claims, or obscuring which entity compounds the medication. FeelGood's published disclaimers - including "Prescription medications require a virtual consultation and approval by a licensed healthcare provider. Results may vary" - and its transparent three-entity structure (platform, OpenLoop Healthcare Partners medical group, third-party pharmacy) reflect the type of disclosure framework FDA's publicly stated consumer-protection concerns specifically address. Buyers can verify FeelGood's LegitScript reference status independently at legitscript.com.

What is LegitScript and why does it matter?

LegitScript is an independent certification and monitoring service for online healthcare and pharmacy platforms. Carrying LegitScript verification means a platform has met compliance standards for legitimate online healthcare operations - including prescription drug practices, licensing, and operational transparency. LegitScript is recognized by major payment processors and advertising platforms as a legitimacy marker. FeelGood's LegitScript seal is publicly verifiable at legitscript.com. In a GLP-1 telehealth space that includes some non-compliant operators, LegitScript status is a meaningful differentiator.

How do I contact FeelGood if I have questions?

FeelGood's published contact information: support@feelgoodmeds.com. The brand states 24/7 support access is included with subscription. For cancellations specifically, email support@feelgoodmeds.com with your name and account email at least 72 hours before your billing date. The patient portal is accessible via the mobile app (iOS/Android) or browser at feelgoodmeds.portal.tellescope.com.

View the current FeelGood GLP-1 offer (official FeelGood page)

What Makes FeelGood Different From Other GLP-1 Telehealth Platforms?

There are now dozens of telehealth platforms offering compounded GLP-1 prescriptions. The differentiation factors that matter to buyers who've done their homework come down to a short list: price, what's included, the clinical infrastructure behind the platform, legitimacy credentials, and support quality.

FeelGood's $149/month entry price is in the lower range of the publicly advertised compounded GLP-1 telehealth market. Its LegitScript verification is a publicly verifiable credential that distinguishes it from unverified competitors. The OpenLoop Healthcare Partners, PC relationship means there's an established medical group structure with documented telehealth consent, state licensure, and compliance infrastructure behind the clinical services - not just a website with a prescriber on call.

The app-first approach and brand-stated 24/7 support position FeelGood for buyers who want consistent access rather than sporadic check-ins. For a medication protocol that requires titration management and side effect oversight, that's a real differentiator from platforms that offer one intake consultation and ship medication without ongoing support.

What FeelGood shares with the broader compounded GLP-1 telehealth category is the regulatory context: compounded medications aren't FDA-approved. That's a uniform feature of the compounded telehealth model, not unique to FeelGood. Brand-name FDA-approved alternatives exist at dramatically higher prices and with insurance/prior-authorization barriers. Buyers are making a tradeoff when they choose the compounded route - FeelGood's job is to make that tradeoff as informed and well-supervised as possible.

Buyer Takeaway: FeelGood's competitive position is price plus legitimacy credentials plus support infrastructure. That combination is real and worth evaluating against alternatives at higher price points. What it doesn't change is the compounded medication regulatory context - that's a category-wide factor all buyers should understand.

The Compounded GLP-1 Window: What the Category Contraction Means for Buyers Deciding Right Now

Here's a piece of context most GLP-1 reviews aren't giving you, because most were written before the category started changing this fast.

In 2022 and 2023, compounded semaglutide and tirzepatide programs expanded rapidly because both drugs were on the FDA's official shortage list - which gave compounders broad legal cover to prepare and distribute them. That shortage exemption started closing in late 2024. By February 2025 for semaglutide and March 2025 for tirzepatide, FDA declared both shortages resolved and transitional exemption windows ended. By early 2026, FDA had publicly announced enforcement actions against multiple compounded GLP-1 telehealth platforms, and in April 2026 formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list - with a public comment period running through June 2026. By mid-2026, a major telehealth platform exited compounded GLP-1 advertising as part of a settlement with Novo Nordisk.

None of that means compounded GLP-1 programs are disappearing tomorrow. But the direction of travel is clear: the category is contracting, the compliance requirements are tightening, and the platforms that operate with transparent legal architecture - LegitScript verification, disclosed medical group, clear compounding pharmacy structure - are the ones most likely to still be running the same program in twelve months that they're running today.

That context reframes the buyer decision. You're not just deciding whether a $149/month compounded GLP-1 program is right for you medically and financially. You're deciding which platform has the structure to still be serving patients at the same terms when you're six months into a titration protocol. That's an availability and continuity question, and it's legitimately urgent in a way that a year ago it wasn't.

FeelGood's structural characteristics - LegitScript, OpenLoop Healthcare Partners medical group, transparent three-entity disclosure, published Terms and Refund Policy, iOS and Android app - are the markers of a platform built for this environment, not against it. Whether that holds is something only ongoing monitoring can confirm. What buyers can do right now is verify the foundational markers, ask the pharmacy question, get the MBG terms in writing, and make an enrollment decision with real information.

Buyer Takeaway: The compounded GLP-1 category that existed in 2023 is not the category that exists in mid-2026. The platforms that continue operating in this environment typically have publicly verifiable structural characteristics consumers can review before enrollment. FeelGood publicly discloses several consumer-reviewable signals. The one gap consumers should address directly - the specific compounding pharmacy name - is a question to ask at support@feelgoodmeds.com before your first billing cycle.

Final Assessment: What This Review Can and Cannot Conclude About FeelGood GLP-1

Everything here comes from publicly available sources: FeelGood's official website, published Terms and Refund Policy, the OpenLoop Healthcare Partners PC telehealth consent, and publicly available FDA and FTC guidance. No product testing. No provider interviews. No internal data access.

What the evidence supports concluding: FeelGood displays the foundational public signals a consumer can look for when evaluating a telehealth GLP-1 platform - a LegitScript verification reference (verify current status at legitscript.com), a publicly documented medical group structure through OpenLoop Healthcare Partners PC, clearly accessible cancellation and refund policies, and a competitive price point that genuinely lowers the access barrier for clinician-supervised compounded GLP-1 treatment. The medical group behind the clinical services is a documented, independently verifiable entity with its own published telehealth consent, SOC 2 compliance certification, and a verifiable physical address. The cancellation process is clear, email-based, and accessible. The compounded medication disclosure is appropriately prominent in the platform's published consent documentation rather than buried in footnotes.

What the evidence doesn't support concluding: whether FeelGood's program will work for you specifically. That's a clinical question, and it has a clinical answer - which is what the intake evaluation exists to provide. It also doesn't resolve the tension between the lander's "Weight Loss Money Back Guarantee" language and the published refund policy's narrower eligibility terms. That requires a direct conversation with FeelGood support before your first billing cycle.

If you're evaluating FeelGood seriously, the verification checklist in this article gives you a better framework than any testimonial on the brand's homepage - because it focuses on the questions that have documented answers and the gaps that require direct buyer-to-brand confirmation before your credit card gets charged. Confirm the Money Back Guarantee terms in writing. Confirm what's included at your specific program tier and what the all-in monthly cost is. Confirm the compounding pharmacy name and its relevant quality credentials. Ask about the titration protocol and what to expect during the first four to six weeks of treatment. Then make your decision with real information rather than promotional assumptions.

View the current FeelGood GLP-1 offer (official FeelGood page)

Additional Buyer Takeaways Across the FeelGood GLP-1 Decision

Buyer Takeaway - On the enrollment process: The digital-first intake is genuinely convenient. The tradeoff for that convenience is a fully digital clinical relationship. Some buyers prefer that. Others want in-person follow-up available. Know which category you're in before committing to a telehealth-only program.

Buyer Takeaway - On the price: $149/month for clinician-supervised compounded GLP-1 injections represents a real reduction in the traditional access barrier. The "starting at" qualifier matters - confirm your specific price before the first charge.

Buyer Takeaway - On the compounding question: "Not FDA-approved" doesn't mean "unsafe" or "ineffective." It means a different regulatory pathway. Compounded medications may be legally prepared and dispensed under applicable state and federal pharmacy law, but they are not FDA-approved, and FDA does not verify compounded drugs for safety, effectiveness, or quality before marketing. That means you're relying on the compounding pharmacy's own quality controls - not FDA pre-market approval - as your primary safety assurance. Asking about those controls, the pharmacy's 503A or 503B status, and any third-party quality accreditation it holds before your first dose is a reasonable and informed thing to do.

Buyer Takeaway - On the testimonials: The before-and-after results on FeelGood's website represent real patients who achieved real outcomes. They also represent the best cases, not the average case. Customer ratings and testimonials are brand-reported and individual experiences vary. The 15-20% average body weight loss claim is brand-stated, not independently audited.

Buyer Takeaway - On the three-entity structure: Understanding that FeelGood (platform), OpenLoop Healthcare Partners PC (medical group), and a compounding pharmacy (medication) are three separate entities matters when you have a complaint or question. Know which entity handles which type of issue before you need to raise one.

Buyer Takeaway - On the app: Download it before your first appointment. The patient portal interface and communication tools are central to the FeelGood experience, especially for ongoing support and titration management.

Buyer Takeaway - On the 4.8/5 rating: The rating is brand-stated. Source and verification methodology aren't documented in publicly available FeelGood materials. Search independently for third-party platform reviews to add context before forming your own assessment.

View the current FeelGood GLP-1 offer (official FeelGood page)

Frequently Raised Concerns About GLP-1 Telehealth Programs and How FeelGood Addresses Them

Buyers who've done any research on GLP-1 telehealth tend to come with a specific set of concerns. Here's how FeelGood's publicly available information addresses each of them.

"I'm worried about compounded medication quality." It's the most common concern and a reasonable one with a specific answer available if you ask for it. Compounded medications are prepared by licensed compounding pharmacies operating under state pharmacy board regulations and federal law - either as 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (larger-scale non-patient-specific compounding subject to additional federal oversight and voluntary FDA inspection). The quality assurance is pharmacy-level rather than FDA-approval-level, which means the standards can vary more across providers than with brand-name FDA-approved drugs whose manufacturing is directly supervised. FeelGood coordinates with a third-party compounding pharmacy whose name isn't publicly documented in available materials reviewed for this article; buyers who want to verify the specific pharmacy's credentials, 503A or 503B status, and any accreditation it holds can request that information from support before enrolling.

"I'm worried about getting stuck in a subscription I can't cancel." The cancellation process is documented, email-based, and available any time. The 72-hour notice window is the critical detail - miss it and you pay one more cycle. That's standard for subscription health services. The refund restrictions are also standard for pharmaceutical services, where medication returned to a pharmacy creates regulatory issues. The concern is valid; the policy addresses it, and the process is accessible.

"I don't trust before-and-after photos." Healthy skepticism here is appropriate. FeelGood's before-and-after patient photos are identified as actual FeelGood patients. FTC rules require that testimonials reflect genuine customer experiences. Whether the outcomes shown are representative of typical results is a separate question - and the brand answers it with "individual results vary" and "results may vary" in its own disclosures.

"I've tried GLP-1 before and had side effects." Relevant clinical history to disclose during intake. Prior GLP-1 intolerance, dose history, and side effect experience should be part of your intake evaluation. Your assigned provider can assess whether a different dosing approach, different formulation, or different medication class is more appropriate. Don't omit it because you're worried it'll disqualify you.

"I can't afford it long-term." Valid financial planning concern for a subscription medication program. GLP-1 medications are not typically considered short-term interventions - weight regain after stopping is documented in clinical literature. Factor in the ongoing monthly cost before enrolling, not just the first month. Know the cancellation process before you start so you're not surprised by billing if circumstances change.

Buyer Takeaway: The concerns people raise about GLP-1 telehealth platforms are legitimate. The answers aren't "don't worry about it" - they're "here's what the documentation shows and here's what you need to ask to fill the gaps." Every concern above has an answerable question attached to it.

Review Methodology and Information Sources for This Article

This article was prepared using publicly available information only. Sources reviewed include: the official FeelGood website at feelgoodmeds.com, the brand's published Cancellation and Refund Policy, Terms of Use (last updated July 2025), the OpenLoop Healthcare Partners, PC telehealth consent form published at openloophealth.com, LegitScript verification data, and category-level published research on GLP-1 receptor agonists from NIDDK, NIH, and peer-reviewed clinical literature. No product samples were received. No provider interviews were conducted. No financial access to FeelGood's internal patient outcome data was obtained. The article reflects information available as of June 2026 - a point in time when the compounded GLP-1 telehealth market is active and competitive, FDA enforcement discretion policy on compounded semaglutide and tirzepatide is subject to ongoing regulatory guidance, and the broader clinical evidence base for GLP-1 receptor agonists continues to expand through newly published long-term follow-up studies. Pricing, policy terms, and program details are subject to change; verify current information at feelgoodmeds.com before enrolling.

Last Updated: June 2026

View the current FeelGood GLP-1 offer (official FeelGood page)

Disclosure and Disclaimers

Affiliate Disclosure: This article contains affiliate links. A commission may be earned from qualifying purchases or enrollments made through links in this article, at no additional cost to the reader.

Advertorial Disclosure: This content is promotional in nature and is intended for consumer education regarding a commercially available telehealth service. This article is a sponsored advertorial review based on publicly available materials. It does not constitute an independent clinical, legal, pharmacy, or laboratory evaluation.

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. FeelGood GLP-1 programs involve prescription medications. All healthcare decisions, including decisions about starting, stopping, or changing prescription medications, should be made in consultation with a qualified licensed healthcare provider. Individual results vary.

Prescription Medication Disclaimer: Prescription medication is available only after consultation and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed. FeelGood does not prescribe medication. Prescriptions are issued by licensed providers affiliated with OpenLoop Healthcare Partners, PC, in their independent clinical judgment.

Compounded Medication Disclosure: Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Compounding pharmacies operate under state and federal pharmaceutical regulations. Consumers should discuss compounded medication status, dosing, risks, alternatives, and pharmacy fulfillment with their assigned licensed provider before starting any compounded medication.

Results Disclaimer: Individual results vary. Brand-stated testimonials, ratings, patient counts, average weight-loss figures, and outcome claims are not independently verified by this publication and should not be interpreted as guarantees of outcome, typicality, or individual experience.

Pricing Disclaimer: Pricing, availability, program terms, refund terms, shipping, HSA/FSA eligibility, and support features are brand-stated and subject to change. Consumers should verify all current details directly with FeelGood at feelgoodmeds.com before enrollment.

Compounded Medication Safety Notice: The FDA has identified concerns involving compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent products, adverse-event reports, and semaglutide salt forms. Consumers should discuss these concerns with their assigned licensed provider and confirm dosing, measurement, storage, and API form before use.

Data Privacy Notice: FeelGood's telehealth services involve the collection and processing of sensitive health information by the platform, a licensed medical group (OpenLoop Healthcare Partners, PC), and a third-party compounding pharmacy. Consumers should review FeelGood's published privacy policy and telehealth consent materials and direct specific data privacy questions to support@feelgoodmeds.com before enrollment.

California Consumer Notice (Subscription Services - CA BPC §17600 / ROSCA 15 USC §8401): FeelGood operates as a subscription service with recurring billing. California residents are entitled to clear disclosure of auto-renewal terms before enrollment. You can cancel any time via email to support@feelgoodmeds.com with advance notice before the billing date. Verify current renewal terms at feelgoodmeds.com/terms-of-use before enrollment.

Geographic and Jurisdiction Notice: FeelGood's Terms of Use specify that Iowa law governs all disputes, with venue in Polk County District Court, Des Moines, Iowa. Healthcare services are provided by licensed providers in the state where the patient is located - availability may vary by state. EU residents should verify whether FeelGood's telehealth services are available in their jurisdiction and confirm pricing, consumer protection rights, and cancellation terms before enrollment.

Material Limitations of This Review: This review is based exclusively on publicly available materials, including the official FeelGood website at feelgoodmeds.com, the brand's published Terms of Use and Cancellation and Refund Policy, the OpenLoop Healthcare Partners, PC telehealth consent, and publicly available regulatory guidance. This publication has not received compensated product samples, has not interviewed brand personnel or licensed providers, has not accessed internal patient outcome data, and has not conducted laboratory or field testing of any medication. Claims described as "brand-stated," "brand-reported," or "according to FeelGood" have not been independently substantiated.

Third-Party Consumer Feedback Platforms: This article references the existence of customer ratings and testimonials reported by FeelGood in general category terms only. Customer ratings and testimonials are brand-reported, not independently audited by this publication. Buyers consulting third-party reviews are encouraged to evaluate them critically and look for verified-purchase indicators where available.

Forward-Looking Statements and Article Accuracy: This article reflects information available as of June 2026. The regulatory enforcement environment for compounded GLP-1 telehealth is rapidly evolving. Product specifications, pricing, policies, availability, and program terms may change after publication without notice. Readers should rely on the official FeelGood website at feelgoodmeds.com as the authoritative source for current program information prior to any enrollment decision.

Reasonable Consumer Standard: This article is written for a general adult consumer audience. Where a statement could otherwise be read as a verified fact, attribution language such as "according to FeelGood," "brand-stated," or "brand-reported" identifies it as a brand claim not independently verified by this publication. Promotional phrases, superlatives, and headline marketing language appearing on FeelGood's website are identified in this article as brand-asserted marketing language, not independent endorsements or performance guarantees.

Publisher Responsibility Disclaimer: The publisher has made reasonable efforts to present accurate information based on available source material at the time of writing. Readers should verify all information directly with FeelGood, their licensed provider, the compounding pharmacy, and relevant regulatory sources before making healthcare or purchase decisions.

Trademark Notice: FeelGood, feelgoodmeds.com, and related marks are the property of FeelGood Health. OpenLoop Healthcare Partners is a mark of OpenLoop Health, Inc. All other brand names referenced in this article are the property of their respective owners. No trademark use here implies endorsement by or affiliation with those trademark holders.

SOURCE: FeelGood

Source: FeelGood